| Assessment Status |
Pre-submission consultation scheduled |
| HTA ID |
24052 |
| Drug |
Lecanemab |
| Brand |
Leqembi® |
| Indication |
Lecanemab (Leqembi®) is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology. |
| Rapid review commissioned |
19/12/2024 |
| Rapid review completed |
28/01/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lecanemab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
29/05/2025 |
